SEC Comment Letter for Nuo Therapeutics, Inc. (AURX) (CIK 0001091596) (AURX) — Aug 24, 2012
Nuo Therapeutics, Inc. (AURX) (CIK 0001091596)
Date: Aug. 24, 2012 · CIK: 0001091596 · Accession: 0000000000-12-046258
AI Filing Summary & Sentiment
File numbers found in text: 001-32518
Letter
August 24, 2012 Via E -mail Andrew Maslan Chief Financial Officer Cytomedix, Inc. 209 Perry Parkway, Suite 7 Gaithersburg, MD 20877
Re: Cytomedix, Inc. Form 10-K for the fiscal year ended December 31, 2011 Filed March 29, 2012 File No . 001-32518
Dear Mr. Maslan :
We have comple ted our review of your filings . We remind you that our comments or changes to disclosure in response to our comments do not foreclose the Commission from taking any action with respect to the company or the filings and the company may not assert staff comments as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States. We urge all persons who are responsible for the accuracy and adequacy of the disclosure in the filings to be certain that the filings include the information the Securities Exchange Act of 1934 and all applicable rules require.
Sincerely,
/s/ Brian Cascio
Show Raw Text
August 24, 2012 Via E -mail Andrew Maslan Chief Financial Officer Cytomedix, Inc. 209 Perry Parkway, Suite 7 Gaithersburg, MD 20877 Re: Cytomedix, Inc. Form 10-K for the fiscal year ended December 31, 2011 Filed March 29, 2012 File No . 001-32518 Dear Mr. Maslan : We have comple ted our review of your filings . We remind you that our comments or changes to disclosure in response to our comments do not foreclose the Commission from taking any action with respect to the company or the filings and the company may not assert staff comments as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States. We urge all persons who are responsible for the accuracy and adequacy of the disclosure in the filings to be certain that the filings include the information the Securities Exchange Act of 1934 and all applicable rules require. Sincerely, /s/ Brian Cascio Brian Cascio Accounting Branch Chief